Corin Group’s FDA Approval for the Cormet(TM) Hip Resurfacing System Paves Way for Stryker to Educate and Advance the Market
KALAMAZOO, Mich., July 3, 2007 /PRNewswire-FirstCall via COMTEX News Network/ — Stryker Corporation (NYSE: SYK) announced that it will begin marketing Corin Group PLC’s (LSE: CRG) Cormet Hip Resurfacing System as early as the third quarter of this year. This follows today’s FDA approval of Cormet and is predicated on a comprehensive surgeon education protocol developed by Stryker and Corin, in cooperation with the FDA, emphasizing patient selection criteria to promote successful outcomes. Stryker’s Orthopaedics division previously secured an exclusive 10-year agreement to market and distribute the Cormet Hip Resurfacing System in the United States.
Interest in hip resurfacing procedures is on the rise globally due to the bone conserving nature of the procedure and anticipated potential benefits related to post-operative activities and range of motion. In these procedures, surgeons replace the acetabulum in much the same way as a conventional total hip but the femoral head is resurfaced rather than removed. Hip resurfacing is viewed by many surgeons as an alternative to traditional hip replacements to help patients indicated for the technology return to their active lifestyles.
Corin is the first manufacturer to receive FDA approval based on a U.S. prospective, multi-center, clinical study that highlights the importance of appropriate patient selection and surgeon education for this emerging technology segment. The results support the need for surgeons to focus on several key anatomic and physiologic factors when determining if resurfacing is the right option for a patient…
…Stryker Corporation is one of the world’s leading medical technology companies with the most broadly based range of products in orthopaedics and a significant presence in other medical specialties. Stryker works with respected medical professionals to help people lead more active and more satisfying lives. The Company’s products include implants used in joint replacement, trauma, craniomaxillofacial and spinal surgeries; biologics; surgical, neurologic, ear, nose & throat and interventional pain equipment; and endoscopic, surgical navigation, communications and digital imaging systems; as well as patient handling and emergency medical equipment. For more information about Stryker, please visit the company web site at http://www.stryker.com.
SOURCE Stryker Corporation
Katherine A. Owen, Vice President, Strategy and Investor Relations of Stryker